SunWay Biotech Past Earnings Performance
Past criteria checks 2/6
SunWay Biotech has been growing earnings at an average annual rate of 42.3%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 24.9% per year. SunWay Biotech's return on equity is 19.3%, and it has net margins of 29.4%.
Key information
42.3%
Earnings growth rate
41.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 24.9% |
| Return on equity | 19.3% |
| Net Margin | 29.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How SunWay Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 322 | 95 | 74 | 42 |
| 31 Mar 23 | 336 | 115 | 70 | 44 |
| 31 Dec 22 | 350 | 135 | 66 | 45 |
| 30 Sep 22 | 377 | 160 | 64 | 47 |
| 30 Jun 22 | 403 | 184 | 62 | 48 |
| 31 Mar 22 | 392 | 176 | 61 | 46 |
| 31 Dec 21 | 380 | 169 | 60 | 43 |
| 30 Sep 21 | 346 | 147 | 57 | 40 |
| 30 Jun 21 | 312 | 125 | 53 | 36 |
| 31 Mar 21 | 313 | 125 | 51 | 35 |
| 31 Dec 20 | 314 | 126 | 50 | 33 |
| 30 Sep 20 | 285 | 109 | 46 | 31 |
| 30 Jun 20 | 255 | 92 | 42 | 29 |
| 31 Mar 20 | 214 | 65 | 41 | 28 |
| 31 Dec 19 | 172 | 38 | 40 | 26 |
| 30 Sep 19 | 160 | 27 | 41 | 27 |
| 30 Jun 19 | 148 | 15 | 41 | 28 |
| 31 Mar 19 | 128 | 1 | 41 | 29 |
| 31 Dec 18 | 109 | -14 | 40 | 30 |
| 30 Sep 18 | 89 | -36 | 40 | 33 |
| 30 Jun 18 | 69 | -58 | 40 | 37 |
| 31 Mar 18 | 70 | -63 | 43 | 37 |
| 31 Dec 17 | 71 | -69 | 45 | 37 |
| 30 Sep 17 | 66 | -68 | 49 | 33 |
| 30 Jun 17 | 61 | -67 | 54 | 28 |
| 31 Mar 17 | 68 | -64 | 56 | 27 |
| 31 Dec 16 | 74 | -62 | 58 | 27 |
| 31 Dec 15 | 41 | -62 | 44 | 25 |
| 31 Dec 14 | 13 | -67 | 38 | 30 |
| 31 Dec 13 | 21 | -71 | 38 | 32 |
Quality Earnings: 1271 has high quality earnings.
Growing Profit Margin: 1271's current net profit margins (29.4%) are lower than last year (45.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1271 has become profitable over the past 5 years, growing earnings by 42.3% per year.
Accelerating Growth: 1271's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1271 had negative earnings growth (-48.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 1271's Return on Equity (19.3%) is considered low.